RotsteinDMontalbanX.Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol2019; 15(5): 287–300.
2.
TintoreMVidal-JordanaASastre-GarrigaJ.Treatment of multiple sclerosis – Success from bench to bedside. Nat Rev Neurol2019; 15(1): 53–58.
3.
StuveOCentonzeD.Treatment decisions for patients with active multiple sclerosis. JAMA Neurol2015; 72(4): 387–389.
4.
OntanedaDTallantyreEKalincikT, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol2019; 18(10): 973–980.
5.
CoccoECaociALoreficeL, et al. Perception of risk and shared decision making process in multiple sclerosis. Expert Rev Neurother2017; 17(2): 173–180.
6.
PardoGJonesDE.The sequence of disease-modifying therapies in relapsing multiple sclerosis: Safety and immunologic considerations. J Neurol2017; 264(12): 2351–2374.
7.
LyndLDHenrichNJHategekaC, et al. Perspectives of patients with multiple sclerosis on drug treatment: A qualitative study. Int J MS Care2018; 20(6): 269–277.
8.
BrownHGabrieleSWhiteJ.Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA. Neurodegener Dis Manag2018; 8(6): 371–376.
9.
RieckmannPCentonzeDElovaaraI, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord2018; 19: 153–160.
10.
CoylePKOhJMagyariM, et al. strategies for female patients of reproductive potential with multiple sclerosis: an evidence-based review. Mult Scler Relat Disord2019; 32: 54–63.
